Article

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

2020-09-01

Abstract excerpt

(Cell 182, 843–854.e1–e12; August 20, 2020) We discovered that values for 2 out of 79 antibodies have unfortunately been wrongly reported. For antibody FnC1t1p2_A5, the IC100 is 50 μg/mL instead of 16 μg/mL; for antibody CnC2t1p1_B10, the IC100 is >100 μg/mL instead of 12.5 μg/mL. For the latter antibody, binding characteristics were also corrected. As a consequence, the total number of neutralizing antibodies rep...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c2b0dd35-8604-5f9a-8f6d-8ba273f56c2d
DOI: 10.1016/j.cell.2020.08.046

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsDOI 10.1016/j.cell.2020.08.046Read

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsSemantic proximity Read

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patientsSemantic proximity Read

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B CellsSemantic proximity Read

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read

Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic MutationSemantic proximity Read

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Semantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

One Thousand SARS-CoV-2 Antibody Structures Reveal Convergent Binding and Near-Universal Immune EscapeSemantic proximity Read

Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades agoSemantic proximity Read

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimerSemantic proximity Read

MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection <i>in vitro</i> and in a hamster model of COVID-19Semantic proximity Read